Boehringer Ingelheim v. Ajanta Pharma: Consent Judgment in 39 Days
Boehringer Ingelheim filed suit against Ajanta Pharma in the District of Delaware asserting four patents covering GLYXAMBI® empagliflozin/linagliptin tablets. The case closed by consent judgment signed by Judge Colm F. Connolly just 39 days after filing, one of the swiftest resolutions in ANDA-related pharmaceutical patent litigation.
Four GLYXAMBI® patents, one consent judgment, 39 days
On August 4, 2023, Boehringer Ingelheim Corporation and Boehringer Ingelheim International GmbH filed a patent infringement action in the District of Delaware against Ajanta Pharma. The complaint asserted four US patents — US9949998B2, US8551957B2, US11090323B2, and US10258637B2 — covering empagliflozin and linagliptin combination tablets, the active ingredients in the branded product GLYXAMBI®. The accused products were Ajanta's proposed 10 mg/5 mg and 25 mg/5 mg empagliflozin/linagliptin tablets, consistent with a Paragraph IV ANDA challenge.
The recorded basis of termination is Consent Judgment. A consent judgment was signed by Judge Colm F. Connolly on September 12, 2023, formally closing the case. As a court-entered judgment agreed to by both parties, it is binding and final. The specific terms agreed between Boehringer Ingelheim and Ajanta Pharma are not disclosed in the available public record.
The 39-day duration from filing to consent judgment is notably short, even by the standards of pharmaceutical patent disputes that settle before claim construction. The speed of resolution suggests the parties reached agreement rapidly, though whether that reflects a pre-negotiated position, a licensing arrangement, or another commercial resolution is not reflected in the public docket. What remains unknown is any market-entry date, royalty, or other condition that may have been incorporated into the judgment.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 39 days
39 days — from filing to consent judgment, well under the median ANDA patent case duration
US9949998B2 and three further patents — empagliflozin/linagliptin combination therapy
Any company developing, filing an ANDA for, or commercialising an empagliflozin/linagliptin fixed-dose combination product in the United States should treat this four-patent portfolio as a primary FTO priority. The Ajanta consent judgment demonstrates that Boehringer Ingelheim actively enforces all four patents simultaneously. Formulators working on SGLT2/DPP-4 combinations — even with modified dosage strengths or excipient profiles — should assess claim scope across US9949998B2, US8551957B2, US11090323B2, and US10258637B2 before advancing to IND or ANDA filing.
Official order — verbatim text
The consent judgment is recorded as signed by Judge Colm F. Connolly on September 12, 2023, closing the case 39 days after filing. The recorded basis of termination is Consent Judgment. As a court-entered order agreed by both parties, the judgment is binding and enforceable. No merits determination — on infringement or patent validity — was made. The specific agreed terms are not disclosed in the available public record.
Consent judgment: what the agreed resolution means for both parties
A court-entered judgment agreed by both parties
A consent judgment is not merely a settlement agreement — it is a binding court order entered by the judge on terms the parties have accepted. Judge Connolly signed the consent judgment on September 12, 2023. This gives it the force of a final court judgment, meaning it is enforceable and, unlike a private settlement, forms part of the public court record. The specific terms of the parties' agreement are not disclosed in the available record.
Binding and finalBoehringer Ingelheim secures a court-entered resolution
For Boehringer Ingelheim, the consent judgment provides a judicially enforceable resolution protecting its four asserted patents covering GLYXAMBI® without requiring full litigation through trial or claim construction. The judgment forecloses Ajanta from launching its proposed empagliflozin/linagliptin tablets on terms inconsistent with the judgment. Any permitted market-entry date or licensing terms are not disclosed in the public record.
Patents protectedAjanta Pharma's generic launch path governed by judgment
For Ajanta Pharma, the consent judgment ends the litigation without a finding of infringement or invalidity being litigated to conclusion. The terms governing any future commercial activity — including whether and when Ajanta may market its 10 mg/5 mg and 25 mg/5 mg empagliflozin/linagliptin tablets — are not disclosed in the available public record. The binding nature of the judgment means Ajanta's path to market, if any, is circumscribed by its agreed terms.
Terms undisclosedGLYXAMBI® patent estate reinforced at district court level
The swift consent judgment, covering all four asserted patents, signals that Boehringer Ingelheim's GLYXAMBI® patent estate presented a credible barrier to Ajanta's generic entry. Other ANDA filers targeting empagliflozin/linagliptin combination products should note that this outcome does not adjudicate validity or claim scope, meaning the patents remain untested on the merits — but also unchallenged by this defendant.
Generic entry risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | /Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Ajanta Pharma | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the SGLT2/DPP-4 combination patent space
Forward-looking patent and innovation intelligence derived from Boehringer Ingelheim's GLYXAMBI® enforcement action — relevant to diabetes combination therapy developers and generic filers.
Boehringer Ingelheim's layered GLYXAMBI® patent estate
Boehringer Ingelheim asserted four patents spanning multiple application families. This layered approach — common in branded pharmaceutical IP strategy — suggests active continuation filing activity around empagliflozin/linagliptin. Monitoring Boehringer's prosecution pipeline for pending continuations or divisionals in this family is essential for any company planning a competing fixed-dose combination product.
Portfolio depthSGLT2/DPP-4 combination filing trends in type 2 diabetes
Fixed-dose SGLT2/DPP-4 combinations are an active area of pharmaceutical patent filing globally. Tracking filing activity by Boehringer Ingelheim, AstraZeneca, Merck, and generic challengers in this space reveals where patent protection is clustering and where formulation white space may exist for novel combination dosage forms or delivery mechanisms.
Filing trendAjanta Pharma's ANDA pipeline in antidiabetic combination therapy
Ajanta Pharma's swift consent judgment in this case — without litigating invalidity — suggests a possible strategic retreat from this patent family. Monitoring Ajanta's subsequent ANDA filings and patent challenge activity in SGLT2 and DPP-4 combination products may signal whether the company is pivoting to less encumbered antidiabetic generics or pursuing parallel challenges elsewhere.
Generic postureFormulation and delivery white space around empagliflozin/linagliptin
The four asserted patents cover specific compositions and methods. Adjacent R&D opportunities may exist in novel delivery systems, modified-release formulations, or triple fixed-dose combinations incorporating empagliflozin or linagliptin with a third active. Eureka white-space analysis can map claim boundaries and identify formulation approaches not captured by the current GLYXAMBI® patent estate.
Innovation gapSimilar ANDA patent cases: SGLT2/DPP-4 combination therapy disputes in Delaware
Explore comparable pharmaceutical patent infringement cases involving empagliflozin, linagliptin, or fixed-dose combination ANDA challenges filed in the District of Delaware.
What this case signals for the SGLT2/DPP-4 combination IP landscape
A 39-day consent judgment across four patents suggests Boehringer Ingelheim's GLYXAMBI® exclusivity position is actively defended and rapidly enforced.
Four-patent assertion strategy raises the cost of ANDA challenges
Asserting four patents simultaneously — spanning composition, formulation, and method claims — forces generic challengers to invalidate or design around an entire patent family, not a single claim. This stacking approach is consistent with branded pharmaceutical practice to maximise litigation leverage and extend effective exclusivity.
39-day resolution is a strong signal of pre-litigation negotiation
Cases resolved by consent judgment within 39 days of filing typically indicate that substantive discussions began before — or immediately after — the complaint was filed. Companies monitoring the GLYXAMBI® ANDA landscape should treat this timeline as evidence that Boehringer Ingelheim moves quickly to resolve challenges, likely on commercially structured terms.
Boehringer-Ingelheim v Ajanta — key questions answered
Boehringer Ingelheim asserted four patents: US9949998B2, US8551957B2, US11090323B2, and US10258637B2. All four cover aspects of empagliflozin and linagliptin combination therapy, the active ingredients in GLYXAMBI®. The accused products were Ajanta's proposed 10 mg/5 mg and 25 mg/5 mg empagliflozin/linagliptin tablets.
The case was resolved by consent judgment, signed by Judge Colm F. Connolly on September 12, 2023 — 39 days after filing. The recorded basis of termination is Consent Judgment. The specific agreed terms are not disclosed in the available public record.
A consent judgment is a binding, court-entered judgment on terms agreed by both parties. Unlike a private settlement, it carries the force of a final court order and is enforceable by the court. In ANDA litigation, consent judgments commonly govern the timing and conditions of any permitted generic market entry, though the specific terms in this case are not disclosed in the public record.
The 39-day timeline from filing to consent judgment is notably short and consistent with cases where substantive discussions preceded or immediately followed filing. Other ANDA filers targeting GLYXAMBI® or empagliflozin/linagliptin combinations should note that Boehringer Ingelheim appears to move quickly to enforce its four-patent portfolio, and that this outcome does not adjudicate patent validity or claim scope.
The case was filed in the District of Delaware and presided over by Judge Colm F. Connolly. Delaware District Court is the predominant venue for ANDA patent litigation in the United States. Judge Connolly signed the consent judgment on September 12, 2023.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.